Teva Pharma (TEVA) Announces U.S. Launch of its Generic Version of SOOLANTRA Cream, 1% for Once Daily Treatment of Rosacea
Get Alerts TEVA Hot Sheet
Overall Analyst Rating:
NEUTRAL (= Flat)
Dividend Yield: 2.1%
EPS Growth %: +30.0%
Join SI Premium – FREE
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd.(NYSE and TASE: TEVA), today announced the U.S. launch of its generic version of once daily SOOLANTRA® (ivermectin) Cream, 1% for the treatment of inflammatory lesions of rosacea.
With nearly 550 generic medicines available, Teva has the largest portfolio of FDA-approved generic products on the market. Currently, 1 in 11 generic prescriptions dispensed in the U.S. is filled with a Teva generic product.
SOOLANTRA® had annual sales of more than $115 million in the U.S., according to IQVIA data as of April 2021.
About Ivermectin Cream 1%
Ivermectin cream, 1% is a prescription medicine used for the treatment of inflammatory lesions of rosacea.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)
- Canopy Growth (CGC) Announces CBI Conversion to Exchangeable Shares, Appoints New Board
- Glacier Bancorp (GBCI) Approved to Acquire Six Montana Branches From HTLF Bank (HTLF)
Create E-mail Alert Related Categories
Corporate NewsRelated Entities
Definitive Agreement, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!